Duvelisib is a first-in-class oral dual inhibitor of phosphoinositide 3-kinase -delta and PI3K-gamma, two enzymes known to help support the growth and survival of malignant B-cells and T-cells.
Verastem is seeking full approval for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and accelerated approval for the treatment of relapsed or refractory follicular lymphoma.
The FDA target action date is October 5, 2018.
Duvelisib is also being developed by Verastem for the treatment of peripheral T-cell lymphoma, and is being investigated in combination with other agents through investigator-sponsored studies.
Verastem is focused on discovering and developing drugs to improve outcomes for patients with cancer. The company's product candidates seek to treat cancer by modulating the local tumor microenvironment, enhancing anti-tumor immunity, and reducing cancer stem cells.
FDA approval streamlines access to Bristol Myers Squibb CAR T cell therapies
Emmaus Life Sciences' Endari label enhancements receive US FDA approval
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress